Concentrations of indoleamine metabolic intermediates in the ventricular cerebrospinal fluid of advanced Parkinson's patients with severe postural instability and gait disorders

Journal of Neural Transmission

Volumn 104, Issue 4-5, 1997, Pages 451-459

  Iacono, R P ^a,c   Kuniyoshi, S M ^a   Ahlman, J R ^a   Zimmerman, G J ^a   Maeda, G ^b   Pearlstein, R D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LLUMC   (United States)

Author keywords

Cerebrospinal fluid (CSF); Parkinson's disease; Postural instability; Serotonin

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; 5 HYDROXYTRYPTOPHAN; AROMATIC LEVO AMINO ACID DECARBOXYLASE; CARBIDOPA; HOMOVANILLIC ACID; INDOLEAMINE; SEROTONIN;

ADULT; AGED; ARTICLE; BODY POSTURE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DYSKINESIA; GAIT DISORDER; HUMAN; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; SEROTONINERGIC TRANSMISSION; TREMOR;

5-HYDROXYTRYPTOPHAN; AGED; BIOGENIC AMINES; CEREBRAL VENTRICLES; GAIT; HOMOVANILLIC ACID; HUMANS; HYDROXYINDOLEACETIC ACID; INDOLES; MIDDLE AGED; OSMOLAR CONCENTRATION; PARKINSON DISEASE; POSTURE; SEROTONIN;

EID: 0030818505     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01277663     Document Type: Article

References (28)

1. Alburges ME, Narang N, Wamsley JK (1993) A sensitive and rapid HPLC-ECD method for the simultaneous analysis of norepinephrine, dopamine, serotonin and their primary metabolites in brain tissue. Biomed Chromatogr 7: 306-310
2. Bloem BR (1992) Postural instability in Parkinson's disease. Clin Neurol Neurosurg 94: S41-45
3. Bonnet AM, Loria Y, Saint-Hilaire MH, Lhermitte F, Agid Y (1987) Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions? Neurology 37: 1539-1542
4. Chase TN, Ng LK (1972) Central monoamine metabolism in Parkinson's disease. Arch Neurol 27: 486-491
5. Chinaglia G, Landwehrmeyer B, Probst A, Palacios JM (1993) Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram. Neuroscience 54: 691-699
6. D'Amato RJ, Zweig RM, Whitehouse PJ, Wenk GL, Singer HS, Mayeux R, Price DL, Snyder SH (1987) Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann Neurol 22: 229-236
7. Furukawa Y, Kondo T, Nishi K, Yokochi F, Narabayashi H (1991) Total biopterin levels in the ventricular CSF of patients with Parkinson's disease: a comparison between akineto-rigid and tremor types. J Neurol Sci 103: 232-237
8. Halliday GM, Blumbergs PC, Cotton RG, Blessing WW, Geffen LB (1990a) Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. Brain Res 510: 104-107
9. Halliday GM, Li YW, Blumbergs PC, Joh TH, Cotton RG, Howe PR, Blessing WW, Geffen LB (1990b) Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann Neurol 27: 373-385
10. Hashiguti H, Nakahara D, Maruyama W, Naoi M, Ikeda T (1993) Simultaneous determination of in vivo hydroxylation of tyrosine and tryptophan in rat striatum by microdialysis-HPLC: relationship between dopamine and serotonin biosynthesis. J Neural transm [Gen Sect] 93: 213-223
11. Iacono RP, Shima F, Lonser RR, Kuniyoshi S, Maeda G, Yamada S (1995) The results, indications, and physiology of posteroventral pallidotomy for patients with Parkinson's disease [see comments]. Neurosurgery 36: 1118-11125 (discussion 1125-1127)
12. Ichinose H, Ohye T, Fujita K, Pantucek F, Lange K, Riederer P, Nagatsu T (1994) Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia. J Neural Transm [Park Dis Dement Sect] 8: 149-158
13. Indo T, Takahashi A (1986) An analysis of long-term L-dopa therapy in 122 cases of Parkinson's disease over 14 years - when should L-dopa therapy be initiated? Jpn J Med 25: 114-121
14. Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, Huber S, Koller W, Olanow C, Shoulson I, et al (1990) Variable expression of Parkinson's disease: a baseline analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40: 1529-1534
15. Jellinger KA, Paulus W (1992) Clinico-pathological correlations in Parkinson's disease. Clin Neurol Neurosurg 94: S86-S88
16. Klawans HL (1986) Individual manifestations of Parkinson's disease after ten or more years of levodopa. Mov Disord 1: 187-192
17. Koller WC, Glatt S, Vetere-Overfield B, Hassanein R (1989) Falls and Parkinson's disease. Clin Neuropharmacol 12: 98-105
18. Koskiniemi M, Laakso J, Kuurne T, Laipio M, Harkonen M (1985) Indole levels in human lumbar and ventricular cerebrospinal fluid and the effect of L-tryptophan administration. Acta Neurol Scand 71: 127-132
19. Melamed E, Zoldan J, Friedberg G, Ziv I, Weizmann A (1996) Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy. Adv Neurol 69: 545-550
20. Narabayashi H, Yokochi F, Ogawa T, Igakura T (1991) Analysis of L-threo-3,4-dihydroxyphenylserine effect on motor and psychological symptoms in Parkinson's disease. No To Shinkei 43: 263-268
21. Paulus W, Jellinger K (1991) The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 50: 743-755
22. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y (1983) Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 275: 321-28
23. Scatton B, Dennis T, L'Heureux R, Monfort JC, Duyckaerts C, Javoy-Agid F (1986) Degeneration of noradrenergic and serotonergic but not dopaminergic neurones in the lumbar spinal cord of parkinsonian patients. Brain Res 380: 181-185
24. Sjostrom R, Ekstedt J, Anggard E (1975) Concentration gradients of monoamine metabolites in human cerebrospinal fluid. J Neurol Neurosurg Psychiatry 38: 666-668
25. Sourkes TL, Young SN, Garelis E, Lal S (1975) Gradients of concentrations of tryptophan and 5-hydroxyindoleacetic acid (5-HIAA) in cerebrospinal fluid (CSF). Acta Vitaminol Enzymol 29: 97-99
26. Strittmatter MM, Cramer H (1992) Parkinson's disease and dementia: clinical and neurochemical correlations. Neuroreport 3: 413-416
27. Tohgi H, Abe T, Takahashi S, Takahashi J, Hamato H (1993) Concentrations of serotonin and its related substances in the cereborspinal fluid of parkinsonian patients and their relations to the severity of symptoms. Neurosci Lett 150: 71-74
28. Trouvin JH, Maubrey MC, Raynal H, Jacquot C (1991) Effect of L-dopa loading on 5-HTP decarboxylation in rat brain areas. Fundam Clin Pharmacol 5: 497-502